Brookstone Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.54M Buy
16,038
+13,108
+447% +$1.77M 0.03% 457
2026
Q1
$374K Sell
2,930
-8,764
-75% -$1.09M ﹤0.01% 964
2025
Q4
$1.43M Sell
11,694
-3,466
-23% -$397K 0.02% 536
2025
Q3
$1.52M Sell
15,160
-391
-3% -$35.2K 0.02% 506
2025
Q2
$1.29M Buy
15,551
+12,489
+408% +$996K 0.02% 504
2025
Q1
$248K Buy
3,062
+391
+15% +$34.9K ﹤0.01% 920
2024
Q4
$241K Sell
2,671
-412
-13% -$39.9K ﹤0.01% 893
2024
Q3
$305K Sell
3,083
-16,122
-84% -$1.58M ﹤0.01% 832
2024
Q2
$1.92M Buy
19,205
+16,213
+542% +$1.45M 0.03% 377
2024
Q1
$284K Buy
+2,992
New +$278K 0.01% 785
2022
Q3
Sell
-10,354
Closed -$874K 838
2022
Q2
$874K Buy
+10,354
New +$777K 0.02% 438
2021
Q1
Sell
-14,048
Closed -$1.98M 559
2020
Q4
$1.98M Sell
14,048
-3,745
-21% -$480K 0.08% 175
2020
Q3
$1.98M Buy
+17,793
New +$1.99M 0.09% 146

Other funds holding XBI

Brookstone Capital Management's XBI Position: Q2 2026 in Review

Brookstone Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 447% in Q2 2026, buying an estimated $1.77M and bringing the position to 16,038 shares worth $2.54M. The position accounts for 0.03% of the portfolio, ranked #457.

Brookstone Capital Management first reported a position in XBI in Q3 2020 and has held it in 13 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Brookstone Capital Management held 16,038 shares of State Street SPDR S&P Biotech ETF worth $2.54M as of Q2 2026.
  • Brookstone Capital Management bought 13,108 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.77M.
  • State Street SPDR S&P Biotech ETF made up 0.03% of Brookstone Capital Management's portfolio in Q2 2026, its #457 holding.
  • Brookstone Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 13 quarters since.
  • 932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.